Trials / Completed
CompletedNCT03604718
Study to Assess the Safety and Effectiveness of Beltavac® Polymerized With Alternaria Alternata
Observational Prospective Study to Assess the Safety and Effectiveness Profile of Beltavac® Polymerized With Alternaria Alternata
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 65 (actual)
- Sponsor
- Probelte Pharma S.L.U. · Industry
- Sex
- All
- Age
- 5 Years
- Healthy volunteers
- Not accepted
Summary
Non-interventional Study to Assess the Safety and Effectiveness Profile of a SCIT Therapy With Beltavac® Polymerized With Alternaria alternata in allergic patients
Detailed description
This prospective open multi-centre non-interventional study assess the safety and effectiveness profile of the subcutaneous allergen-specific immunotherapy with Beltavac® Polymerized in Alternaria alternata allergic patients (children and adults) in routine medical care. Patients receive a rush schedule administration every month for a year. They attend at least 4 study visits to inform about the adverse reactions, the self reported symptoms and the medication intake.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Beltavac® Polymerized with Alternaria alternata | Adminstration of Beltavac® Polymerized with Alternaria alternata according to the routine clinical practice |
Timeline
- Start date
- 2018-06-07
- Primary completion
- 2023-01-20
- Completion
- 2023-01-20
- First posted
- 2018-07-27
- Last updated
- 2023-05-11
Locations
13 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT03604718. Inclusion in this directory is not an endorsement.